EQT agrees to buy Corza Medical biosurgery unit
The acquisition of Corza Biosurgery will add TachoSil to EQT’s healthcare portfolio and lift EQT X to an expected 80% to 85% investment level.
By Amanda Ross · Deals Correspondent
· 2 min read
EQT has agreed to acquire Corza Biosurgery from Corza Medical, PE Hub reported, in a healthcare deal centred on TachoSil, a surgical patch used to control bleeding and seal tissue. The transaction is expected to leave EQT X 80% to 85% invested, according to PE Hub.
The business being acquired comprises TachoSil, described by PE Hub as a dual-action active biologic patch for use during surgery. The product’s role is to combine haemostatic support, which helps control bleeding, with tissue-sealing functionality at the surgical site.
EQT plans to back TachoSil by investing in faster commercial development, broader geographic reach and further acquisitions to create a larger biosurgery platform, PE Hub reported. In private equity, that platform approach typically involves using an initial asset as the base for additional transactions in related products or capabilities.
The deal adds to EQT’s exposure to healthcare and medical products through its EQT X fund. PE Hub said the fund is expected to be 80% to 85% invested after the transaction, a measure that indicates how much of the fund’s capital has been allocated or committed to investments.
Corza Medical is selling the biosurgery business, while EQT will become the owner upon completion of the transaction. PE Hub did not report financial terms in the publicly available details.
Governance plan
Sheri McCoy, previously chair of Johnson & Johnson’s Surgical Care Group, will become board chair when the transaction closes, according to PE Hub. Her appointment places an executive with surgical-care experience in a senior governance role for the business under EQT ownership.
The stated investment plan focuses on three areas: expanding commercial execution for TachoSil, entering or building presence in additional markets, and pursuing mergers and acquisitions to broaden the biosurgery platform. Each of those levers can affect how a medical-products business scales, though the pace and scope of investment were not specified.
The acquisition comes as private equity firms continue to target healthcare subsectors where specialised products can support recurring clinical demand. In this case, the asset identified by PE Hub is a surgical patch used in operating settings, with EQT’s stated strategy tied to commercial growth and add-on acquisitions rather than a single-product holding.
Completion remains the next stated milestone. PE Hub reported that McCoy’s board chair role begins upon closing, but did not provide a closing date in the publicly available information.
This story draws on original reporting from PE Hub.
